The FACTS about women and pre-exposure prophylaxis

Lancet HIV. 2015 Jun;2(6):e228. doi: 10.1016/S2352-3018(15)00080-6. Epub 2015 May 27.

Authors

Dominika Seidman¹, Shannon Weber², Erika Aaron³, Deborah Cohan², Robert Grant⁴

Affiliations

¹ University of California San Francisco, CA, USA. Electronic address: dominika.seidmand@ucsf.edu.
² University of California San Francisco, CA, USA.
³ Drexel University, Philadelphia, PA, USA.
⁴ University of California San Francisco, CA, USA; Gladstone Institutes, San Francisco, CA, USA.

PMID: 26423194
DOI: 10.1016/S2352-3018(15)00080-6

No abstract available

Publication types

Letter
Comment

MeSH terms

Adenine / therapeutic use
Anti-HIV Agents / therapeutic use
Antibiotic Prophylaxis
Female
HIV Infections / drug therapy*
HIV-1
Humans
Post-Exposure Prophylaxis
Pre-Exposure Prophylaxis*
Rabies / drug therapy
Rabies Vaccines / therapeutic use
Women

Substances

Anti-HIV Agents
Rabies Vaccines
Adenine